Close Menu

manufacturing agreement

In August, the UK government announced a 5.8 million order for DnaNudge's COVID-19 test kits to enable their rollout in UK NHS hospitals and out-of-hospital locations.

Sherlock Bio recently received US Food and Drug Administration Emergency Use Authorization for the kit, which uses CRISPR to detect the virus in patient samples.

Alphazyme will manufacture three Codexis enzymes, including a new high-fidelity DNA polymerase, and gain comarketing rights to certain other Codexis enzymes.

Co-Diagnostics' test, which recently received Emergency Use Authorization in the US, is designed to detect the RdRp gene of the SARS-CoV-2 virus.

Yourgene will use its manufacturing facility at Citylabs in Manchester to ramp up production of the test, which was developed by Novacyt's Primerdesign division.

The product uses spin columns to extract high molecular weight DNA with an average length of 100 kb or more from animal and bacterial cells.

North Carolina-based BioSkryb develops sample preparation kits based on proprietary primary template-directed amplification chemistry.

RNAssist's products are designed for biomolecule stabilization, tissue fixation, and microbial inactivation in a range of applications including RNA sequencing.

Stratec is producing the microfluidic chips for Vortex' VTX-1 system, which enables the enrichment and isolation of circulating tumor cells.

Aldevron will manufacture IDT's patented S. pyogenes HiFi Cas9 mutant for research, clinical, and commercial uses.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.